Page last updated: 2024-08-05 11:17:14
aromatic compound
A cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character.
ChEBI ID: 33655
Members (11)
| Member | Definition | Role |
|---|---|---|
| 1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one | 1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one | |
| 1,3-diphenylpropane | 1,3-Diphenylpropane | |
| 2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol | 2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol | |
| 2',6'-dimethoxychalcone | 2',6'-dimethoxychalcone | |
| 4-dimethylamino-2',4',6'-trimethoxychalcone | 4-dimethylamino-2',4',6'-trimethoxychalcone | |
| CHIC-35 | An organic heterotricyclic compound resulting from the formal fusion of the 2-3 bond of 5-chloroindole with the 2-3 bond of cycloheptanecarboxamide (the S enantiomer). It is a potent, cell-permeable, metabolically stable and selective inhibitor of the deacetylase SIRT1. | CHIC-35 |
| diprafenone | diprafenone | |
| etafenone | etafenone | |
| MMP-9-IN-1 | A secondary carboxamide resulting from the formal condensation of the carboxy group of [(4-oxo-6-propyl-1,4-dihydropyrimidin-2-yl)sulfanyl]acetic acid with the amino group of 4-(difluoromethoxy)aniline. It is a specific matrix metalloproteinase-9 (MMP-9) inhibitor. | MMP-9-IN-1 |
| N-(1,3-diphenylpropan-2-ylideneamino)-2-hydroxybenzamide | N-(1,3-diphenylpropan-2-ylideneamino)-2-hydroxybenzamide | |
| yoda 1 | A member of the class of thiadiazoles that is 1,3,4-thiadiazole substituted by pyrazin-2-yl and (2,6-dichlorobenzyl)sulfanediyl groups at positions 2 and 5, respectively. It is a selective activator of mechanosensitive channel piezo1. | yoda 1 |
Research
Studies (101)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 25 (24.75) | 18.7374 |
| 1990's | 18 (17.82) | 18.2507 |
| 2000's | 9 (8.91) | 29.6817 |
| 2010's | 23 (22.77) | 24.3611 |
| 2020's | 26 (25.74) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (3.91%) | 5.53% |
| Reviews | 5 (3.91%) | 6.00% |
| Case Studies | 1 (0.78%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 117 (91.41%) | 84.16% |